3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
35
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Myelodysplastic Syndromes
19
Lymphoma, Non-Hodgkin
11
Hodgkin Disease
10
Multiple Myeloma
8
Leukemia, Biphenotypic, Acute
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Leukemia
7
Burkitt Lymphoma
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Myeloproliferative Disorders
6
Neuroblastoma
5
Lymphoma, Mantle-Cell
5
Lymphoma, Large B-Cell, Diffuse
5
Anemia, Refractory, with Excess of Blasts
5
Recurrence
4
Lymphoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Medulloblastoma
3
Lymphoma, T-Cell
3
Lymphoma, Follicular
3
Leukemia, Myelomonocytic, Chronic
3
Sarcoma
2
Rhabdomyosarcoma
2
Primary Myelofibrosis
2
Neoplasms, Plasma Cell
2
Myelodysplastic-Myeloproliferative Diseases
2
Interventions
Specimen Handling
1
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Granulocyte Colony-Stimulating Factor
×
1 year
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled